# üöÄ NEXT STEPS GUIDE
## Patent Filing and SBIR Grant Application

**Status:** ‚úÖ Documents revised and ready
**Date:** November 23, 2025

---

## üìã COMPLETED TASKS

‚úÖ Identified technical flaw (PLGA incompatibility with phospholipid chemistry)
‚úÖ Revised invention to use CsA-phospholipid prodrugs integrated into plant EV membranes
‚úÖ Completely rewrote SBIR Specific Aims (4 pages)
‚úÖ Completely rewrote Invention Disclosure (26 pages)
‚úÖ Compiled both documents to PDF
‚úÖ Acknowledged prior art on CsA-phospholipid prodrugs
‚úÖ Clearly defined novelty as carrier integration (not prodrug chemistry)

---

## üéØ IMMEDIATE ACTIONS (This Week)

### 1. Review Documents with PI
**Action:** Send PDFs to Dr. Maria Beatriz Herrera Sanchez
**Files to send:**
- `SBIR_Specific_Aims_PDEV_Prodrug.pdf`
- `Invention_Disclosure_PDEV_Prodrug.pdf`
- `REVISION_SUMMARY.md`

**Key points to discuss:**
- Confirm she agrees with the dual-level mechanism (PDEV targeting + PLA2 activation)
- Discuss timeline for procuring/synthesizing CsA-phospholipid prodrugs
- Identify co-inventor (medicinal chemist for prodrug synthesis?)
- Review budget allocation for contract synthesis ($5K-10K per variant)

### 2. Consult Patent Attorney
**Action:** Schedule meeting within 48 hours
**Materials to provide:**
- `Invention_Disclosure_PDEV_Prodrug.pdf` (complete disclosure)
- `REVISION_SUMMARY.md` (explains novelty vs. prior art)

**Key discussion points:**
- **Prior art acknowledgment:** CsA-phospholipid prodrugs exist in literature (cited in disclosure)
- **Our novelty:** Integration into plant EV membranes as carrier
- **Claim strategy:** Composition (PDEV + integrated prodrug) + method (incorporation process)
- **Geographic coverage:** US, EU, Canada, Japan, China, Brazil
- **Timeline:** File provisional patent within 7 days to establish priority

### 3. File Provisional Patent
**Action:** Submit to USPTO (or attorney handles)
**Deadline:** Within 7 days (urgency: establish priority date before any public disclosure)
**Title:** "Plant Extracellular Vesicle-Integrated CsA-Phospholipid Prodrug Platform for PLA2-Activated Oral Drug Delivery"
**Inventors:**
- Maria Beatriz Herrera Sanchez, PhD (Lead Inventor)
- [Co-Inventor Name], PhD (to be determined)

**Cost estimate:** $1,000-3,000 (attorney fees + filing)

---

## üî¨ PRELIMINARY DATA GENERATION (Weeks 2-4)

### Goal: Generate proof-of-concept data for SBIR application

#### Task 1: Procure CsA-Phospholipid Prodrugs
**Options:**
1. **Contract synthesis (RECOMMENDED for Phase I):**
   - Contact: Avanti Polar Lipids (avantilipids.com/contact-us)
   - Alternative: ChemCruz (Santa Cruz Biotechnology)
   - Request: 3 prodrug variants
     - Variant A: 1-palmitoyl-2-(CsA-succinate)-sn-glycero-3-phosphocholine
     - Variant B: 1-stearoyl-2-(CsA-glutarate)-sn-glycero-3-phosphocholine
     - Variant C: 1-palmitoyl-2-(CsA-homoserine)-sn-glycero-3-phosphocholine
   - Quantity: 10-50 mg per variant (sufficient for in vitro studies)
   - Cost: $5,000-10,000 per variant
   - Timeline: 8-12 weeks

2. **In-house synthesis (if medicinal chemistry expertise available):**
   - Start with lysophosphatidylcholine (commercially available)
   - Follow synthesis protocol in Invention Disclosure, Example 1
   - Timeline: 4-6 weeks (if experienced chemist)

**Decision:** Discuss with Dr. Herrera and budget availability

#### Task 2: Plant EV Isolation
**Responsibility:** Dr. Herrera's lab (ExoVitae)
**Protocol:** Invention Disclosure, Section 4.2
**Source:** Fresh citrus juice (2L ‚Üí ~250 mg EV protein)
**Timeline:** 1 week
**Characterization:**
- Particle concentration (NTA)
- Size and PDI (DLS)
- Morphology (TEM)
- EV markers (Western blot: CD63, TSG101)

#### Task 3: Prodrug Integration into PDEV Membranes
**Responsibility:** Dr. Herrera's lab
**Protocol:** Invention Disclosure, Section 4.3 (co-incubation method)
**Key experiments:**
- Test 3-5 prodrug:PDEV ratios (1:100, 1:50, 1:20, 1:10, 1:5 mol:mol)
- Quantify incorporation by LC-MS of lipid extracts
- Target: ‚â•5-10 mol% prodrug of total PDEV lipids
- Verify structural integrity (TEM, DLS, zeta potential)
**Timeline:** 2 weeks

#### Task 4: PLA2-Triggered Release Assay
**Responsibility:** Dr. Herrera's lab
**Protocol:** Invention Disclosure, Example 4
**Materials needed:**
- Recombinant sPLA2-IIA (commercial, e.g., Sigma-Aldrich, Cayman Chemical)
- HPLC or LC-MS/MS for CsA quantification
**Key experiment:**
- Incubate PDEV-prodrug with:
  - PBS alone (control)
  - sPLA2-IIA (1 Œºg/mL)
- Quantify CsA release at 0, 1, 3, 6, 24h
- Target: ‚â•3-fold increase in CsA release with PLA2 vs. control
**Timeline:** 1 week

#### Task 5: In Vitro T-Cell Suppression (Optional, if time permits)
**Responsibility:** Dr. Herrera's lab or collaborator
**Protocol:** Invention Disclosure, Example 5
**Key experiment:**
- Activate human PBMCs with anti-CD3/CD28
- Test: Free CsA, Free prodrug, PDEV-prodrug (with/without PLA2)
- Measure IL-2 by ELISA
- Target: PDEV-prodrug + PLA2 achieves ‚â•50% suppression at half dose vs. free CsA
**Timeline:** 2 weeks

### Summary of Preliminary Data Timeline
- **Weeks 1-2:** Procure prodrugs (if contract synthesis, 8-12 weeks delivery)
- **Week 2:** Isolate citrus EVs
- **Weeks 3-4:** Integrate prodrugs into EVs, quantify incorporation
- **Week 4:** PLA2-triggered release assay
- **(Optional) Weeks 5-6:** In vitro T-cell suppression

**Realistic timeline for SBIR submission:** 10-12 weeks (if using contract synthesis) OR 6-8 weeks (if prodrugs already available)

---

## üìù SBIR PHASE I APPLICATION (Weeks 4-12)

### Grant Mechanism
**Program:** NIH SBIR Phase I
**Institute:** NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases)
**Funding:** $500,000 (direct costs), 12 months

### Application Components
1. **Specific Aims (1 page):** Use `SBIR_Specific_Aims_PDEV_Prodrug.pdf` as-is or with minor edits after preliminary data
2. **Research Strategy (6 pages):**
   - Significance (1.5 pages): Market, unmet need, prior art
   - Innovation (1 page): Dual-level control, carrier integration novelty
   - Approach (3.5 pages): Expand Aims 1-3 from Specific Aims, add preliminary data
3. **Commercialization Plan (1-2 pages):** Section 7 of Invention Disclosure
4. **Budget Justification:** Allocate $500K across:
   - Personnel: $200K (PI 20%, postdoc/research scientist 100%, technician 50%)
   - Materials & Supplies: $150K (prodrug synthesis, EVs, assays, mice)
   - Equipment: $50K (LC-MS access fees, NTA, TEM service)
   - Travel: $10K (conferences, collaborator meetings)
   - Other: $40K (animal facility fees, subcontracts)
   - Indirect costs: $50K (if allowed; some SBIR programs cap indirects)
5. **Biographical Sketches:** Dr. Herrera + Co-Investigators
6. **Letters of Support:** From potential pharma partners (Takeda, Ferring, AbbVie) or collaborators

### Submission Deadlines
**Check NIH SBIR calendar:** Typically 3 deadlines per year (April, August, December)
**Next deadline:** [To be determined based on current date]

---

## üí∞ BUDGET ESTIMATE

### Provisional Patent Filing
- Attorney review & filing: $1,000-3,000
- **Total:** ~$2,000

### Preliminary Data Generation (Pre-SBIR)
- Prodrug synthesis (3 variants, contract): $15,000-30,000
- Plant EV isolation (materials, not labor): $2,000
- LC-MS analysis (external service): $3,000
- Recombinant PLA2 enzyme: $500
- HPLC consumables: $1,000
- **Total:** ~$25,000-40,000

**Funding source options:**
- Institutional seed grant
- Angel investor
- Founder/PI self-funding
- Delay prodrug synthesis until SBIR Phase I funded (file application based on prophetic examples only)

### SBIR Phase I (If Awarded)
- 12 months, $500,000 direct costs
- Complete Aims 1-3 from Specific Aims document

---

## üìß EMAIL TEMPLATE FOR DR. HERRERA

**Subject:** Revised Invention Disclosure & SBIR Grant Strategy - Ready for Review

Dear Dr. Herrera,

I've completed a comprehensive revision of the invention disclosure and SBIR specific aims based on technical corrections. The key change:

**Original approach (FLAWED):** CsA-loaded PLGA nanoparticles nested inside plant EVs (technically incompatible)

**Revised approach (CORRECT):** CsA-phospholipid prodrugs integrated directly into plant EV membranes

This approach:
1. Builds on validated prodrug chemistry from published literature (reduces technical risk)
2. Provides clear novelty through carrier integration (plant EVs)
3. Maintains dual-level control (EV targeting + PLA2 activation)
4. Strengthens patent position (composition + method claims)

**Attached documents:**
- `SBIR_Specific_Aims_PDEV_Prodrug.pdf` (4 pages) - Camera-ready for grant submission
- `Invention_Disclosure_PDEV_Prodrug.pdf` (26 pages) - Complete disclosure for patent attorney
- `REVISION_SUMMARY.md` - Detailed explanation of all changes

**Next steps I recommend:**
1. **Review documents** - Confirm you agree with the revised technical approach
2. **Patent attorney consultation** - Schedule meeting within 48 hours
3. **Provisional patent filing** - File within 7 days to establish priority
4. **Preliminary data** - Discuss timeline for procuring CsA-prodrugs and isolating citrus EVs

Please let me know if you have any questions or would like to schedule a call to discuss.

Best regards,
[Your Name]

---

## üìß EMAIL TEMPLATE FOR PATENT ATTORNEY

**Subject:** Urgent - Invention Disclosure Review for Provisional Patent Filing

Dear [Attorney Name],

I'm writing on behalf of Dr. Maria Beatriz Herrera Sanchez regarding a new invention for oral drug delivery using plant-derived extracellular vesicles. We need to file a provisional patent within the next 7 days to establish priority.

**Invention Overview:**
- CsA-phospholipid prodrugs with PLA2-cleavable bonds integrated into plant extracellular vesicle membranes
- Application: Inflammatory bowel disease (IBD) treatment with reduced systemic toxicity
- Market: $500M+ IBD segment, $2B+ global CsA market

**Critical Prior Art:**
- CsA-phospholipid prodrugs with PLA2-cleavable bonds are described in literature (acknowledged in disclosure)
- **Our novelty:** Integration into plant EV membranes as carrier (GI protection, tissue targeting, GRAS status)

**Attached documents:**
- `Invention_Disclosure_PDEV_Prodrug.pdf` (26 pages) - Complete technical disclosure
- `REVISION_SUMMARY.md` - Explains novelty vs. prior art

**Key discussion needed:**
1. Claim strategy: Composition (PDEV + integrated prodrug) vs. method (incorporation process)
2. Geographic coverage: US, EU, Canada, Japan, China, Brazil
3. Timeline: Provisional now, full utility within 12 months
4. Budget: Estimate for provisional + full utility filings

Please let me know your availability for a consultation call this week.

Best regards,
[Your Name]

---

## ‚úÖ CHECKLIST

### This Week
- [ ] Send PDFs to Dr. Maria Beatriz Herrera Sanchez
- [ ] Schedule patent attorney consultation
- [ ] File provisional patent (through attorney)

### Weeks 2-4
- [ ] Procure or synthesize CsA-phospholipid prodrugs (3 variants)
- [ ] Isolate citrus EVs (Dr. Herrera's lab)
- [ ] Demonstrate prodrug integration into PDEV membranes
- [ ] Perform PLA2-triggered release assay
- [ ] (Optional) In vitro T-cell suppression assay

### Weeks 4-12
- [ ] Complete SBIR Phase I application
- [ ] Obtain letters of support from potential partners
- [ ] Submit SBIR application to NIH NIDDK
- [ ] Convert provisional patent to full utility (Month 12)

---

**Status:** ‚úÖ Documents ready for immediate action
**Urgency:** HIGH (provisional patent filing within 7 days)
**Next Action:** Contact Dr. Herrera and patent attorney TODAY

---

## üìû KEY CONTACTS

**Principal Investigator:**
- Dr. Maria Beatriz Herrera Sanchez, PhD
- ExoVitae Lab
- [Contact information to be added]

**Patent Attorney:**
- [Name and firm to be added]

**Contract Chemistry Labs (for prodrug synthesis):**
- Avanti Polar Lipids: avantilipids.com/contact-us
- ChemCruz (Santa Cruz Biotechnology): scbt.com/contact-us

**NIH SBIR Program:**
- SBIR website: sbir.nih.gov
- NIDDK contacts: niddk.nih.gov/research-funding/research-programs

---

**Date Created:** November 23, 2025
**Last Updated:** November 23, 2025
